Microbot Medical Inc. (MBOT) — SEC Filings
Microbot Medical Inc. (MBOT) — 50 SEC filings. Latest: 8-K (Apr 13, 2026). Includes 44 8-K, 3 10-Q, 2 DEF 14A.
View Microbot Medical Inc. on SEC EDGAR
Overview
Microbot Medical Inc. (MBOT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 13, 2026: Microbot Medical Inc. filed an 8-K on April 13, 2026, to disclose information under Regulation FD and other events. The filing includes financial statements and exhibits, with specific documents like the 8-K form, an exhibit EX-99.1, and graphical representations. The company is categorized under SI
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 1 bearish, 48 neutral, 1 mixed. The dominant filing sentiment for Microbot Medical Inc. is neutral.
Filing Type Overview
Microbot Medical Inc. (MBOT) has filed 44 8-K, 3 10-Q, 2 DEF 14A, 1 10-K with the SEC between Jan 2025 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of MBOT's 46 recent filings, 2 were flagged as high-risk, 17 as medium-risk, and 27 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$9.678M |
| EPS | -$0.25 |
| Debt-to-Equity | N/A |
| Cash Position | $6.704M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Israel
- Hamas
- Assad regime
- Houthis
- Iranian regime
Industry Context
Microbot Medical operates in the highly competitive and capital-intensive medical device sector, specifically focusing on robotic surgical technologies. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Companies in this space often rely on substantial funding rounds to advance their technologies through clinical trials and FDA approval processes before achieving commercial viability.
Top Tags
8-K (16) · disclosure (15) · equity-sale (12) · financials (11) · material-agreement (6) · 8-k (5) · SEC Filing (4) · filing (4) · regulation-fd (3) · corporate-disclosure (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| CIK | 0000883975 | Company Identification Number for Microbot Medical Inc. |
| Accession Number | 0001493152-26-016293 | Unique identifier for the SEC filing |
| Filing Date | 2026-04-13 | Date the 8-K was accepted by the SEC |
| Net Loss | $9.678M | For the nine months ended September 30, 2025, widened from $8.051M in 2024 |
| Cash and Marketable Securities | $80.158M | As of September 30, 2025, excluding restricted cash, up from $5.470M at Dec 31, 2024 |
| Proceeds from Issuance of Common Stock and Warrants | $83.733M | For the nine months ended September 30, 2025, significantly boosting cash |
| Operating Loss | $10.605M | For the nine months ended September 30, 2025, increased from $8.195M in 2024 |
| Shares of Common Stock Outstanding | 67,158,044 | As of November 12, 2025, indicating significant dilution from 19,399,513 shares at Dec 31, 2024 |
| Research and Development Expenses | $4.741M | For the nine months ended September 30, 2025, increased from $4.646M in 2024 |
| Sales, General and Administrative Expenses | $5.864M | For the nine months ended September 30, 2025, increased from $3.549M in 2024 |
| Basic and Diluted Net Loss Per Share | $0.25 | For the nine months ended September 30, 2025, improved from $0.53 in 2024 due to increased share count |
| Revenue | $0 | No revenue for Q2 2025 or YTD 2025, indicating pre-commercial stage. |
| Net Loss (Q2 2025) | $3.8M | Decreased from $4.1M in Q2 2024, showing a slight improvement in loss management. |
| Net Loss (YTD 2025) | $7.6M | Decreased from $8.1M in YTD 2024, a 7.3% reduction in loss. |
| R&D Expenses (YTD 2025) | $4.4M | Continued significant investment in product development, crucial for future revenue. |
Frequently Asked Questions
What are the latest SEC filings for Microbot Medical Inc. (MBOT)?
Microbot Medical Inc. has 50 recent SEC filings from Jan 2025 to Apr 2026, including 44 8-K, 3 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of MBOT filings?
Across 50 filings, the sentiment breakdown is: 1 bearish, 48 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Microbot Medical Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Microbot Medical Inc. (MBOT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Microbot Medical Inc.?
Key financial highlights from Microbot Medical Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for MBOT?
The investment thesis for MBOT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Microbot Medical Inc.?
Key executives identified across Microbot Medical Inc.'s filings include Israel, Hamas, Assad regime, Houthis, Iranian regime.
What are the main risk factors for Microbot Medical Inc. stock?
Of MBOT's 46 assessed filings, 2 were flagged high-risk, 17 medium-risk, and 27 low-risk.
What are recent predictions and forward guidance from Microbot Medical Inc.?
Forward guidance and predictions for Microbot Medical Inc. are extracted from SEC filings as they are enriched.